Effect of a day-trip to altitude (2500 m) on exercise performance in pulmonary hypertension: randomised crossover trial.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
05
05
2021
accepted:
21
06
2021
entrez:
15
10
2021
pubmed:
16
10
2021
medline:
16
10
2021
Statut:
epublish
Résumé
To investigate exercise performance and hypoxia-related health effects in patients with pulmonary hypertension (PH) during a high-altitude sojourn. In a randomised crossover trial in stable (same therapy for >4 weeks) patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) with resting arterial oxygen tension ( 28 PAH/CTEPH patients (n=15/n=13); 13 females; mean±sd age 63±15 years were included. After >3 h at 2500 m This randomised crossover study showed that the majority of PH patients tolerate a day-trip to 2500 m well. At high
Identifiants
pubmed: 34651040
doi: 10.1183/23120541.00314-2021
pii: 00314-2021
pmc: PMC8502941
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: S.R. Schneider has nothing to disclose. Conflict of interest: L.C. Mayer has nothing to disclose. Conflict of interest: M. Lichtblau has nothing to disclose. Conflict of interest: C. Berlier has nothing to disclose. Conflict of interest: E.I. Schwarz has nothing to disclose. Conflict of interest: S. Saxer has nothing to disclose. Conflict of interest: L. Tan has nothing to disclose. M. Furian has nothing to disclose. Conflict of interest: K.E. Bloch has nothing to disclose. Conflict of interest: S. Ulrich reports grants from Johnson and Johnson SA, Switzerland, during the conduct of the study; and grants from the Swiss National Science Foundation and Zurich Lung, grants and personal fees from Orpha Swiss, and personal fees from Actelion SA and MSD SA, outside the submitted work.
Références
Scand J Med Sci Sports. 2007 Oct;17(5):588-94
pubmed: 17316377
Respiration. 2018;95(6):422-432
pubmed: 29502125
J Am Heart Assoc. 2020 Nov 17;9(22):e018123
pubmed: 33146048
Chest. 2016 Jul;150(1):57-67
pubmed: 26892603
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
COPD. 2005 Mar;2(1):131-6
pubmed: 17136973
Respiration. 2017;93(2):90-98
pubmed: 28068656
Open Heart. 2017 Jan 20;4(1):e000532
pubmed: 28123765
J Appl Physiol (1985). 2017 Dec 1;123(6):1657-1670
pubmed: 28775065
High Alt Med Biol. 2018 Mar;19(1):4-6
pubmed: 29583031
Eur Respir J. 2003 Dec;22(6):1019-25
pubmed: 14680095
J Am Soc Echocardiogr. 2019 Jan;32(1):1-64
pubmed: 30282592
Chest. 2018 Oct;154(4):788-797
pubmed: 29909285
Circ J. 2016 Aug 25;80(9):2019-25
pubmed: 27488283
J Appl Physiol (1985). 1992 May;72(5):2018-23
pubmed: 1601813
Exp Physiol. 2005 Jul;90(4):437-46
pubmed: 15802289
Sleep. 2019 Jan 1;42(1):
pubmed: 30517695
Circulation. 2010 Jul 13;122(2):191-225
pubmed: 20585013
Int J Cardiol. 2018 Nov 1;270:262-267
pubmed: 29891241
Chest. 2021 Feb;159(2):757-771
pubmed: 32918899
Neth Heart J. 2010 Mar;18(3):118-21
pubmed: 20390061
Int J Chron Obstruct Pulmon Dis. 2018 Oct 26;13:3529-3538
pubmed: 30464436
Exp Physiol. 2015 Oct;100(10):1187-98
pubmed: 26260891
Eur Respir J. 2020 Aug 20;56(2):
pubmed: 32430419
Natl J Maxillofac Surg. 2013 Jul;4(2):136-41
pubmed: 24665166
J Appl Physiol (1985). 2014 May 1;116(9):1189-96
pubmed: 24610534
High Alt Med Biol. 2015 Mar;16(1):11-7
pubmed: 25803140
Chest. 2015 Apr;147(4):943-950
pubmed: 25846528
Circulation. 1985 Dec;72(6):1270-8
pubmed: 4064271
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545971
Front Med (Lausanne). 2020 Sep 02;7:502
pubmed: 32984379
Am J Cardiol. 2009 Jun 1;103(11):1605-9
pubmed: 19463523
Am J Respir Crit Care Med. 2016 May 15;193(10):1185
pubmed: 27174486
Scand J Med Sci Sports. 2013 Aug;23(4):458-67
pubmed: 22093058
Scand J Med Sci Sports. 2015 Dec;25 Suppl 4:53-9
pubmed: 26589118